Autopsy report · NCT02092961
Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study
Cause of deathFunding or business
“AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.”
Life of this trial
- Registered 3 years 1 month after it had already started.
- Ran for about 2 years 5 months before it stopped.
- 198 participants enrolled.
- Results were posted on the registry 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Conditions
- Rheumatoid Arthritis
- Interventions
- Fostamatinib; Adalimumab; Placebo of Fostamatinib; Placebo of Adalimumab
- Participants
- 198
- Sites
- 21
- Countries
- Bulgaria, Canada, Czechia, Germany, Hungary, Netherlands, Poland, Russia, South Africa, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.